842 lines
42 KiB
Plaintext
842 lines
42 KiB
Plaintext
Newsgroups: alt.drugs
|
|
|
|
Cognition-Enhancement Drugs
|
|
|
|
|
|
|
|
This text has been excerpted from MEGABRAIN REPORT: THE
|
|
PSYCHOTECHNOLOGY NEWSLETTER. Included here are dosages,
|
|
precautions, and mail-order sources for three intelligence and
|
|
memory enhancing substances. Please feel free to duplicate this
|
|
excerpt and put it onto other bulletin boards or conference
|
|
systems. For a copy of the full length article, including
|
|
references, contact MEGABRAIN REPORT, POB 2744, Sausalito, CA
|
|
94965, Phone: (415) 332-8323, FAX: (415) 332-8327.
|
|
|
|
The authors of this article are Michael Hutchison and John
|
|
Morgenthaler. Michael Hutchison is the editor and publisher of
|
|
MEGABRAIN REPORT and can be contacted there (see the address
|
|
above). He is also the author of the books, MegaBrain: New Tools
|
|
and Techniques For Brain Growth and Mind Expansion, The Book of
|
|
Floating, and the recently published Anatomy of Sex and Power: An
|
|
Investigation of Mind Body Politics.
|
|
|
|
John Morgenthaler is the co-author with Ward Dean, MD, of a full
|
|
length book on over thirty cognition enhancing compounds. The book
|
|
includes an index, references, and sources of compounds. John can
|
|
be contacted at POB 483 Santa Cruz, CA 95061, Phone: (800)
|
|
669-2030, MCI mail address: 3144541. A free copy of the book goes
|
|
to anyone who posts this article to another bulletin board or
|
|
conference system.
|
|
|
|
|
|
COGNITION-ENHANCEMENT DRUGS
|
|
by Michael Hutchison and John Morgenthaler
|
|
|
|
Picture this: You have a business meeting tomorrow with your
|
|
Japanese distributor. This meeting requires that you be in top form
|
|
for some critical negotiations. You have several reports to go
|
|
over, many facts to memorize, and above all you have to get some
|
|
rest.
|
|
|
|
Your first step? A trip to the drug store, of course. A meeting
|
|
like this is much too important to take on without fine-tuning your
|
|
biochemistry. You must create the optimal neurochemical conditions
|
|
for learning and creativity. You ask the druggist, who then points
|
|
you towards the shelf of cognitive enhancement
|
|
compounds. You load up your basket with bottles of piracetam,
|
|
vasopressin, hydergine, choline, DMAE, and maybe a little
|
|
centrophenoxine.
|
|
|
|
After arriving home, and taking the appropriate doses of each of
|
|
these you go into your study to slip on your cranial electric
|
|
stimulator along with your light and sound device. You know from
|
|
your experience and that of many pioneers in the consciousness
|
|
revolution that this particular combination of chemicals and brain
|
|
machines has a synergistic effect that will create the optimal
|
|
psychobiological state for the tasks that lie ahead. You can be
|
|
sure that your Japanese counterparts are engaged in a similar
|
|
manner.
|
|
|
|
After an hour in your study you feel very different. You are
|
|
relaxed, yet alert and creative. Your brainwave activity has
|
|
altered, and an EEG would show that it has become more regular and
|
|
has increased in amplitude in certain frequencies, causing you to
|
|
feel simultaneously profoundly relaxed yet in a state of intense
|
|
concentration, loose and creative as well as mentally quick and
|
|
alert. A brain-mapping device would show that the two hemispheres
|
|
of your brain were in a state of "superconnection," with an
|
|
enormous increase in the amount of information flowing between the
|
|
hemispheres. At the same time, the rate of metabolism and the
|
|
energy level of your brain cells has sharply increased. You are now
|
|
in the optimal state to imprint new memories, to plan new and more
|
|
creative strategies, to visually rehearse every detail of your
|
|
upcoming meeting...
|
|
|
|
Sound far-fetched? Well, both the brain machines and the
|
|
cognitive enhancement compounds already exist. Megabrain
|
|
described a variety of devices that show evidence of enhancing
|
|
cognition (for a summary of several recent studies suggesting that
|
|
CES devices can have clear cognition-boosting effects see the
|
|
"Research Update" elsewhere in this issue); and the book also
|
|
mentioned the cognition-enhancing effects of such neurochemicals
|
|
as vasopressin and MSH-ACTH 4-10. Since then other mind-
|
|
magnifying drugs have emerged as well as even more astonishing
|
|
evidence of their ability to amplify learning, memory and
|
|
thinking. What we don't know is how to best use them together, or
|
|
even whether they should be used together.
|
|
|
|
That's what we want to find out. The problem, as many of you are
|
|
aware, is that it is extremely difficult for those interested in
|
|
performing research into the effects of brain machines to obtain
|
|
the necessary funding and support. Mainstream science,
|
|
particularly those elements in control of doling out grants and
|
|
funds to support research, and many of the universities and
|
|
institutions engaged in research, seem to have little interest in
|
|
investigating these machines. What research is done usually
|
|
involves the therapeutic applications of the devices rather that
|
|
the induction of peak performance brain states.
|
|
|
|
On the other hand, huge amounts of money are being spent for
|
|
research into cognition enhancing drugs. But much of the research
|
|
is being done by the big pharmaceutical companies, who are racing
|
|
with each other to develop patentable memory enhancement drugs and
|
|
to obtain FDA approval for these compounds. Since the FDA is
|
|
primarily oriented toward treating diseases in a medical context,
|
|
and has not shown much interest in giving its approval to drugs
|
|
that simply improve people's memories or boost intelligence, the
|
|
pharmaceutical companies are directing their efforts toward gaining
|
|
approval for their cognition-enhancement drugs as
|
|
treatments for medical problems such as Alzheimer's disease,
|
|
multiple-infarct dementia and senility. Since financial analysts
|
|
estimate that such cognitive drugs could quickly produce sales of
|
|
well over a billion dollars a year in the U.S. alone, and
|
|
ultimately outsell antibiotics and tranquilizers, the competition
|
|
is fierce, and these companies are in no mood to investigate ways
|
|
their substances might work synergistically or in combination with
|
|
other substances or other mechanisms such as mind machines.
|
|
|
|
Also, since their efforts are directed toward drugs that are
|
|
patentable, these companies have little interest in exploring the
|
|
cognition enhancement properties of substances that cannot be
|
|
patented. Vitamin C is a good example: in a controlled study in
|
|
which healthy individuals were tested both for levels of vitamin
|
|
C and IQ, those with higher levels of the vitamin averaged 5 points
|
|
higher in IQ; when those with the lower levels of the vitamin were
|
|
given vitamin C supplements, their IQ scores
|
|
increased by over 3.5 points. In some way, Vitamin C is a
|
|
cognition-enhancing substance. But, of course no one can patent
|
|
vitamin C, which is cheap and readily available.
|
|
|
|
In another example, one widely available and unpatentable
|
|
substance (DHEA) is rumored to have demonstrated in a recent study
|
|
some success in, among other things, treating AIDS, as well as
|
|
cognition enhancement; however, the drug company involved in the
|
|
experiments is now apparently trying to conceal the
|
|
discoveries about DHEA until it can develop some variant that is
|
|
patentable (i.e. has commercial value), and has obtained a court
|
|
order forbidding the scientist in charge of the study to even speak
|
|
with anyone about the matter.
|
|
|
|
|
|
WE HAVE MET THE GUINEA PIG AND IT IS US
|
|
|
|
And so, MEGABRAIN REPORT has concluded that if we really want more
|
|
research into mind-machine mind-food interactions we'd better start
|
|
doing it ourselves. Thus we ask you to join us in a series of
|
|
surveys, tests and assessments designed to explore the interactions
|
|
between brain machines and cognitive enhancement compounds. This
|
|
is not to say we are advising you to take any of the cognition-
|
|
enhancement substances we describe. No! We do not advise you to
|
|
take these compounds, just as we do not advise you to use mind
|
|
machines or do anything to enhance your mental
|
|
functioning. High level mental functioning can be exceedingly
|
|
dangerous and have frightening and unpredictable side effects, as
|
|
individuals from Socrates to Jesus to Galileo have discovered.
|
|
|
|
However, we do have reason to believe that many of you are by
|
|
nature curious, given to exploration and even experimentation--
|
|
that, in fact, many of you are already making use of some of these
|
|
cognition-boosting nutrients. This being so, it seems clear to us
|
|
that you have information that would be of interest and value to
|
|
the rest of us. It's also clear that if there are
|
|
hundreds or even thousands of you with such information, then by
|
|
gathering it together, we can synthesize it, analyze it, begin to
|
|
search for trends, tendencies, proclivities, and perhaps even make
|
|
some important connections.
|
|
|
|
The first part of the survey is intended to be an open-ended
|
|
exploration rather that a rigorous scientific study or an attempt
|
|
to confirm an existing hypotheses. We hope not for solid
|
|
conclusions or hard data, but rather to discover and delineate some
|
|
interesting avenues for future research.
|
|
|
|
In a later issue, we will report on the early survey results. It's
|
|
possible--though we cannot guarantee it--that in
|
|
investigating the subjective responses we hope to receive from
|
|
MEGABRAIN REPORT readers we will discover some trends. We can use
|
|
this information to guide us in designing a more focused study for
|
|
part two of the survey.
|
|
|
|
For example, we might receive many reports that the effects of
|
|
piracetam are amplified when used with the light and sound
|
|
devices. Then we could plan to focus more deeply on the
|
|
particular machine/compound interaction, investigating the
|
|
interactive effects over differing periods of time, using
|
|
different sound and light frequencies and modes, and in various
|
|
areas, such as memory, reaction speed, creativity and so on.
|
|
|
|
In this issue, we will introduce some of the more interesting
|
|
compounds for cognitive enhancement, provide information about how
|
|
to obtain each of them, present some methods for assessing and
|
|
evaluating your own brain state and tracing your progress, and
|
|
present a simple questionnaire. These self-assessment methods and
|
|
our initial survey appear at the end of this article. First we will
|
|
describe a few of the most promising cognition enhancing
|
|
substances.
|
|
|
|
NOOTROPIC DRUGS
|
|
|
|
PIRACETAM
|
|
|
|
"Last year a friend took me to hear Sun Ra and his Intergalactic
|
|
Arkestra as a birthday present. I had just received a bottle of
|
|
800 mg tablets of Piracetam. My friend and I each took nine of the
|
|
tablets (an "attack dose" they call it in the literature) before
|
|
entering the hall. The music began 30 minutes later. I found myself
|
|
able to concentrate as never before. I was
|
|
completely lucid with absolutely no sense of intoxication. For the
|
|
first time in my life I could hear each individuals horn's timbre
|
|
(Sun Ra has about 10 horn players, often all playing massed
|
|
harmonies.) My friend has worked as a professional
|
|
saxophone player. He, too, reported extraordinary hearing and
|
|
concentration abilities. My ears felt as though the were being
|
|
stimulated from all directions at once, but the feeling was
|
|
entirely pleasant. I was enthralled."
|
|
|
|
Piracetam has been the subject of intensive research for over 15
|
|
years, and has not only proven to be a powerful intelligence
|
|
booster and cerebral stimulant, but also, even in massive acute
|
|
and chronic dosages, appears to be nontoxic and to produce no side
|
|
effects (it's so nontoxic one FDA employee reportedly
|
|
claimed that since huge doses produce no toxic effects, it can't
|
|
possibly have any pharmacological effects and must be
|
|
physiologically inert). It is so remarkable in its effects and
|
|
safety that its discovery by UCB Laboratories in Belgium sent
|
|
virtually every other major pharmaceutical company scrambling to
|
|
develop its own cerebral stimulant. This "Smart pill race" has
|
|
resulted in the creation of a new drug category called the
|
|
nootropics, from the Greek words noos (mind) and tropein (turn),
|
|
meaning "acting on the mind".
|
|
|
|
Some of the nootropic drugs being tested now on humans include
|
|
vinpocetine (being developed by Ayerst Laboratories), which speeds
|
|
up learning, improves memory and recall and seems to block the
|
|
action of substances that disrupt memory; aniracetam
|
|
(Hoffman-La Roche), which appears to be about ten times more potent
|
|
in improving and protecting memory than piracetam,
|
|
pramiracetam (Warner-Lambert/Parke Davis), which seems to improve
|
|
learning and memory by enhancing the firing of neurons in the
|
|
hippocampus (a key to the formation of long-term memories), and
|
|
oxiracetam (Ciba-Geigy), apparently two to three times as
|
|
powerful as piracetam (intriguingly, research shows that when
|
|
oxiracetam is given to pregnant rats their offspring proved more
|
|
intelligent that control groups--similar findings have been
|
|
reported for the offspring of pregnant rats kept in "enriched
|
|
environments," as described in the "Research Update" elsewhere in
|
|
this issue). All of these substances seem remarkably nontoxic and
|
|
free of side effects.
|
|
|
|
As yet, there is no nootropic drug that is approved by the FDA for
|
|
sale in the US, but, keenly aware of the multi-billion dollar
|
|
potential of nootropics, the drug companies are pouring big bucks
|
|
into research that will satisfy FDA requirements by proving how
|
|
they work (still not well understood), and by proving their
|
|
effectiveness in treating medical problems such as Alzheimer's
|
|
disease and senility. In this article we will focus on the most
|
|
extensively tested and widely available nootropic compound,
|
|
piracetam.
|
|
|
|
Piracetam has been proven to boost learning and memory in normal
|
|
subjects as well as those who suffer cognitive deficits, and is
|
|
also a cognitive enhancer under conditions of hypoxia, or too
|
|
little oxygen (recent expeditions to climb Mt. Everest have
|
|
included piracetam as an "essential" medication to treat
|
|
frostbite and memory lapses causes by altitude). A variety of
|
|
clinical studies with human subjects, including studies of young
|
|
healthy volunteers, healthy middle-aged subjects with some memory
|
|
decline, elderly subjects, elderly subjects with senility, and
|
|
alcoholics, have proven that piracetam enhances cortical
|
|
vigilance, improves integration of information processing,
|
|
improves attention span and concentration, and can produce
|
|
dramatic improvements in both direct and delayed recall of verbal
|
|
learning.
|
|
|
|
It's effective in the treatment of dyslexia, stroke, alcoholism,
|
|
vertigo, senile dementia, sickle-cell anemia, and many other
|
|
conditions, enhances the brain's resistance to various injuries
|
|
and boosts its ability to recover from injuries, protects the brain
|
|
against chemicals such as barbiturates and cyanides, and is widely
|
|
used throughout Europe and Latin America (where it is sold over the
|
|
counter).
|
|
|
|
The subjective effect described by a lot of people is that it
|
|
"wakes up your brain". In fact, it selectively stimulates the
|
|
anterior or frontal part of the forebrain--that part of the brain
|
|
that has evolved most recently, rapidly and remarkably in the
|
|
course of our evolution from ape to human, and which is the seat
|
|
of our "higher functions."
|
|
|
|
Piracetam works in a number of ways to increase energy within the
|
|
brain. First, it steps up the production of adenosine
|
|
triphosphate (ATP), the energy storage and energy generating
|
|
molecules within our cells. It also boosts cerebral metabolism by
|
|
improving cerebral microcirculation (blood flow), increasing the
|
|
brain's use of glucose, and increasing the brain's oxygen
|
|
utilization. It also seems to enhance protein syntheses in the
|
|
brain (it's been proven that protein synthesis is an essential step
|
|
in laying down long-term memories).
|
|
|
|
SUPERCONNECTING THE BRAIN. Perhaps the most intriguing aspect of
|
|
piracetam is that it has been proven to increase the flow of
|
|
information between the right and left hemispheres of the brain.
|
|
As a result of experiments with human subjects one researcher
|
|
concluded that piracetam causes the hemispheres to become
|
|
"superconnected." Since there's increasing evidence that high level
|
|
brain states--brilliance, insight, creativity, flow, peak
|
|
performance, being "in the zone"--are a product of the integrated
|
|
and synergistic functioning of both hemispheres simultaneously, we
|
|
might suspect that piracetam enhances not only simple learning and
|
|
memory but creative or syntheses thinking.
|
|
|
|
Piracetam's capacity to superconnect the hemispheres becomes even
|
|
more intriguing in light of the evidence indicating that many of
|
|
the most widely used mind machines and techniques for brain
|
|
enhancement (such as binaural beat frequencies and the sound and
|
|
light machines) function in part by facilitating integrated
|
|
hemispheric functioning. This raises the possibility that since
|
|
both the machines and piracetam seem to facilitate
|
|
interhemispheric communication, there might be a potentiating or
|
|
synergistic effect when such mind machines are used in
|
|
combination with piracetam, resulting in a quantum leap in brain-
|
|
enhancement effects.
|
|
|
|
PRECAUTIONS: Piracetam may increase the effects of certain drugs,
|
|
such as amphetamines and psychotropics. Adverse effects are rare
|
|
but include insomnia, psychomotor agitation, nausea, headaches and
|
|
gastrointestinal distress.
|
|
|
|
DOSAGE: Piracetam is supplied in 400mg or 800mg tablets. The usual
|
|
dose is 2400-4800 mg per day in three divided doses. Some
|
|
literature recommends that the first two days a high "attack" dose
|
|
should be taken. We have noticed that when some people first take
|
|
piracetam they do not notice any effect until they take a high
|
|
dose. Thereafter, they may notice that a lower dosage is
|
|
sufficient. The drug takes effect in 30 to 60 minutes.
|
|
|
|
SOURCES: piracetam is not sold in the US. It can be purchased over
|
|
the counter in Mexico or by mail order from the address below.
|
|
|
|
HYDERGINE
|
|
|
|
"I first tried Hydergine six years ago during a visit to see my
|
|
Dad at Christmas. He and I started taking 9mg and results were
|
|
apparent to us both within two days. He was in his 40s, and began
|
|
to remember events from when he was in his 20s as clearly as if
|
|
they'd happened yesterday. What was interesting was that the events
|
|
were nothing outstanding--just ordinary times. In other words, the
|
|
everyday events had been stored away all these years, it just took
|
|
some chemical prodding to jog them loose into the conscious mind.
|
|
I was in my early 20s and had similar memories going back to my
|
|
childhood years. A unique opportunity had been presented to us to
|
|
sit down and really share in the joys that our life had brought us.
|
|
What a gift!"
|
|
|
|
A wealth of research going back over 20 years suggests that
|
|
Hydergine may be what psychologist-pharmacist Ross Pelton calls
|
|
"the ultimate smart pill." The substance, whose generic name is
|
|
ergoloid mesylates, is made from a natural, organic source: the
|
|
ergot fungus of rye plants (it was discovered at Sandoz
|
|
laboratories by the visionary chemist Dr. Albert Hofmann, also
|
|
known for his discovery of another ergot derivative, LSD 25). It
|
|
increases mental abilities, prevents damage to brain cells, and
|
|
may even be able to reverse existing damage to brain cells.
|
|
|
|
Hydergine acts in several ways to enhance mental capabilities and
|
|
to slow down or reverse the aging processes in the brain. A few of
|
|
the huge number of beneficial effects scientists have
|
|
attributed to Hydergine include: increased protein syntheses in
|
|
the brain; reduced accumulation of lipofuscin in the brain;
|
|
increased quantities of blood and oxygen delivered to the brain;
|
|
improvement of memory, learning and intelligence; beneficial
|
|
improvements in brainwave activity; increased metabolism in brain
|
|
cells; normalization of blood pressure; and increased production
|
|
of such neurotransmitters as dopamine and norepinephrine
|
|
(neurochemical messengers essential to the formation of memory,
|
|
and also associated with arousal, alertness, elation and
|
|
pleasure). Hydergine also functions as a powerful antioxidant and
|
|
thus protects the brain against the damage caused by those
|
|
infamous rascally free radicals (unstable and extremely reactive
|
|
molecules produced by normal metabolism, which cause damage
|
|
associated with aging, cancer and cardiovascular disease).
|
|
|
|
One way that Hydergine may enhance brain functioning is by
|
|
mimicking the effect of a substance called nerve growth factor
|
|
(NGF). NGF promotes the growth of dendrites--the long branching
|
|
fibers by which neurons receive information from other neurons.
|
|
Scientists studying the effects of learning on the brain have found
|
|
it is directly related to dendritic growth. Hydergine seems to work
|
|
by the same neurochemical pathway as NGF to produce neural growth.
|
|
|
|
While Hydergine is widely used for the treatment of senility,
|
|
scientists have also studied its effects, both short term and long
|
|
term, in normal healthy humans; these studies noted
|
|
significant improvements in a variety of cognitive function,
|
|
including alertness, memory, reaction time, abstract reasoning and
|
|
cognitive processing ability.
|
|
|
|
PRECAUTIONS: If too large a dose is used when first taking
|
|
Hydergine, it may cause slight nausea, gastric disturbance, or
|
|
headache. Overall, Hydergine does not produce and serious side
|
|
effects, it is non-toxic even at very large doses and it is
|
|
contraindicated only for individuals who have chronic or acute
|
|
psychosis.
|
|
|
|
DOSAGE: The US recommended dosage is 3mg per day, however, the
|
|
European recommended dosage is 9 mg per day taken in three
|
|
divided doses. Most of the research has been done at levels of 9
|
|
to 12 mg per day or higher, and there is some evidence that 3 mg
|
|
per day is simply insufficient for significant cognition-
|
|
enhancement effects. It may take several weeks or even months
|
|
before Hydergine produces noticeable effects. Hydergine (though
|
|
not its generic counterpart) is available in a sublingual form,
|
|
and there is evidence that sublingual doses reach the brain in
|
|
greater quantity.
|
|
|
|
SOURCES: Hydergine is available in the USA with a doctor's
|
|
prescription, and approved by the FDA for the treatment of senile
|
|
dementia and insufficient blood circulation to the brain--your
|
|
doctor may not be familiar with the uses discussed. It can also be
|
|
purchased over the counter in Mexico or by mail order from overseas
|
|
(see below). In many cases these mail order companies sell the
|
|
generic form, Ergoloid Mesylates. The FDA has rated the generic as
|
|
biologically equivalent to the Sandoz product. More testing needs
|
|
to be done on the question.
|
|
|
|
VASOPRESSIN
|
|
|
|
"The most immediate result I get from using vasopressin is
|
|
increased clarity and alertness. I can be logical without the usual
|
|
speediness associated with caffeine use. After five minutes I've
|
|
noticed that I'm busily accomplishing tasks that I'd been putting
|
|
off for a week. The duration is about two hours for the energetic
|
|
feelings. Overall, I feel my short-term memory recall improving
|
|
over the past two weeks of using vasopressin. It seems that the
|
|
longer I use it, the more I can rely on my mind to be a portable
|
|
note pad."
|
|
|
|
"I have smoked pot on a more or less (usually more) daily basis
|
|
for 20 years. When I read that vasopressin is inhibited by pot, I
|
|
found a source for buying some. Now I notice that when I use
|
|
vasopressin with marijuana I still get stoned, but I have little
|
|
or none of the 'dummying down' effect of the pot. And what a
|
|
surprise to find that vasopressin intensifies orgasms!"
|
|
|
|
Vasopressin, called "the memory hormone," is a natural brain
|
|
peptide, stimulated by acetylcholine and released in the
|
|
pituitary. It actually helps create, imprint, and store memories,
|
|
and is essential to remembering. Apparently vasopressin is
|
|
involved in picking out and chunking together related bits of
|
|
information from the stream of consciousness, integrating these
|
|
chunks into coherent structures, and then "imprinting" these images
|
|
or concepts into long-term memory by transforming
|
|
electrical impulses into complex proteins that contain memories
|
|
and are stored away in the brain. The act of remembering the stored
|
|
information is also mediated by vasopressin.
|
|
|
|
Over 20 years ago scientists discovered that vasopressin had
|
|
extraordinary effects on the memory of laboratory animals--
|
|
preventing chemically and electrically induced amnesia, actually
|
|
reversing amnesia, and dramatically boosting the memory and
|
|
intelligence of normal animals. These findings spurred much
|
|
research into the cognition-enhancement effect of vasopressin on
|
|
humans. Among the key findings are that small doses of the
|
|
hormone can have striking success in quickly reversing traumatic
|
|
amnesia (amnesia caused by injuries such as car crashes), can
|
|
reverse age-related memory loss and actually restore lost
|
|
memories, and can produce sharp improvements in learning and memory
|
|
using measures such as abstract and verbal memory,
|
|
organizational capacities, recall, attention, concentration, focus,
|
|
short-term memory, optical memory, and long-term memory. It also
|
|
boosts performance in such areas as reaction speed, visual
|
|
discrimination, and coordination.
|
|
|
|
Vasopressin pours out during moments of trauma or extreme
|
|
arousal, which may explain why those times seem to be so deeply
|
|
imprinted in our brains, and are remembered with such clarity.
|
|
Vasopressin is also released by cocaine, LSD, amphetamines,
|
|
Ritalin, and Pemoline (Cylert). Those who make frequent use of
|
|
these drugs deplete their brain's vasopressin supply. The result
|
|
is depression, and a decline in cognitive function. The frequent
|
|
user's response to this depression is to take more of the drug,
|
|
thus trying to wring more vasopressin out of their depleted brain:
|
|
ultimately the well runs dry. Vasopressin, however, is not a drug
|
|
but the actual brain hormone that has been depleted, so it can
|
|
produce dramatic and virtually instantaneous improvements in mood
|
|
and mental functioning.
|
|
|
|
Unlike stimulants, alcohol and marijuana do not deplete but
|
|
actually suppress the release of vasopressin, which could account
|
|
for the loss of memory many have noticed when drunk or stoned, or
|
|
when trying to remember events that occurred while they were high.
|
|
Vasopressin can reduce the harmful effects of these drugs and
|
|
enhance alertness, reaction speed and concentration.
|
|
|
|
Anecdotal evidence suggests that vasopressin can produce a state
|
|
of euphoria accompanied by self-confidence, energy,
|
|
assertiveness, and a sensation of extreme mental clarity. Many
|
|
believe it is ideal for situations in which lots of new
|
|
information needs to be processed and remembered--such as
|
|
studying for an exam, learning a language, ploughing through
|
|
difficult or complex works. Some use it for more mundane
|
|
purposes, such as when they have to drive late at night and want
|
|
to remain alert.
|
|
|
|
PRECAUTIONS: Vasopressin can occasionally produce the following
|
|
side effects; runny nose, nasal congestion, irritation of the nasal
|
|
passages, headache, abdominal cramps, and increased bowel
|
|
movements. Angina sufferers should not use vasopressin, since it
|
|
can trigger angina pains. Vasopressin has not been proven to be
|
|
safe for use during pregnancy.
|
|
|
|
DOSAGE: Vasopressin usually comes in a nasal spray bottle. Most
|
|
studies showing memory improvement have been done with a dose of
|
|
12 to 16 USP per day, which is one whiff in each nostril three to
|
|
four times per day. Vasopressin produces a noticeable effect within
|
|
seconds.
|
|
|
|
SOURCES: Vasopressin (known as Diapid and produced by Sandoz) is
|
|
available in the USA with a doctor's prescription, but keep in mind
|
|
that your doctor may not be familiar with the uses we have
|
|
discussed (it is approved by the FDA for treatment of diabetes
|
|
insipidus). It can also be purchased over the counter in Mexico or
|
|
by mail order from overseas (see below).
|
|
|
|
HOW TO OBTAIN COGNITION-ENHANCEMENT SUBSTANCES BY MAIL ORDER.
|
|
|
|
While some of the substances described above are not available in
|
|
the U.S., or are available only by prescription, it is easy and
|
|
quite legal to obtain these substances by mail order. One reason
|
|
some of these substances are not available in the U.S. is that they
|
|
have not yet gone through the extraordinarily expensive and lengthy
|
|
process required to obtain FDA approval. This does not mean however
|
|
that it is not quite legal to use these substances. And some of the
|
|
substances have been approved by the FDA for limited medical
|
|
application. This does not mean that it is not quite proper to use
|
|
these substances for "unapproved" purposes.
|
|
|
|
In the April, 1982 issue of the FDA Drug Bulletin, the agency
|
|
included a policy statement clarifying the question of
|
|
"unapproved" uses for drugs, clearly stating that "'unapproved'
|
|
uses may be appropriate and rational in certain circumstances, and
|
|
may, in fact, reflect approaches to drug therapy that have been
|
|
extensively reported in medical literature... Valid new uses for
|
|
drugs already on the market are often first discovered
|
|
through serendipitous observations and therapeutic innovation." In
|
|
sum, the FDA clearly approves of the "unapproved" uses as an
|
|
important means for innovation and discovery.
|
|
|
|
Also, though it is not widely known, a July, 1989 FDA ruling now
|
|
makes it quite legal to import effective drugs used elsewhere but
|
|
not available in the U.S. The FDA now allows the importation and
|
|
mail shipment of a three month supply of drugs, for personal use,
|
|
as long as they are regarded as safe in other countries. The new
|
|
ruling, FDA pilot guidelines chapter 971, was made as a result of
|
|
heavy pressure from AIDS political action groups, which insisted
|
|
AIDS sufferers were denied access to potentially life-saving
|
|
substances that were widely used abroad but were still unapproved
|
|
for use in the U.S.
|
|
|
|
InHome Health Services, a mail order pharmacy in Switzerland, is
|
|
one of a number of companies established in response to this new
|
|
FDA ruling. InHome carries a wide variety of drugs for cognitive
|
|
enhancement, life extension, and the treatment of AIDS which are
|
|
not available in the US.
|
|
|
|
All of the drugs discussed here can be purchased without a
|
|
prescription. You can request a full price sheet by writing to:
|
|
InHome Health Services, Dept. E, POB 3112, CH-2800 Delemont,
|
|
Switzerland. Those who want to order some of the substances
|
|
described above right away may send a personal check for the amount
|
|
of the item(s) plus $13 for shipping. Some sample prices (in June,
|
|
1990) are:
|
|
|
|
* Centrophenoxine (250mg x 60) $19
|
|
* Hydergine (4.5mg x 28 tablets) $16.50
|
|
* Phenytoin (Generic Dilantin, 100mg x 100) $8.80
|
|
* Piracetam (800mg x 60 tablets) $16.60
|
|
* Sulbutiamine (200mg x 30) $12.50
|
|
* Vasopressin (5ml spray) $8.75
|
|
|
|
You must include the following signed statement with your order.
|
|
"I hereby declare that the products I am purchasing are not for
|
|
commercial resale. They are for my personal use only. The supply
|
|
ordered does not exceed three months usage, and they are used with
|
|
the consent of my physician."
|
|
|
|
Another company with higher prices, but possibly faster service is:
|
|
|
|
INTERLAB
|
|
PO Box 587
|
|
Newport Pagnell
|
|
Bucks MK 16 8AA England
|
|
|
|
Again include this signed statement with your order: "I hereby
|
|
declare that the products I am purchasing are not for commercial
|
|
resale. They are for my personal use only. The supply ordered does
|
|
not exceed three months usage, and they are used with the consent
|
|
of my physician."
|
|
|
|
~References:
|
|
|
|
Piracetam
|
|
|
|
Anderson, K., Anderson, L. Orphan Drugs. Los Angeles, CA: The Body
|
|
Press, 1983, p. 169.
|
|
Bartus, Raymond T., et al. "Profound Effects of Combining Choline
|
|
and Piracetam on Memory Enhancement and Cholinergic Function
|
|
in Aged Rats." Neurobiology of Aging. 1981, Vol. 2, pp.
|
|
105-11.
|
|
Buresova, O., Bures, J. "Piracetam-Induced Facilitation of
|
|
Interhemispheric Transfer of Visual Information in Rats."
|
|
Psychopharmacologia (Berlin). 1976, Vol. 46, pp. 93-102.
|
|
Bylinsky, G. "Medicine's Next Marvel: The Memory Pill." Fortune.
|
|
January 20, 1986, pp. 68-72.
|
|
Chase, C.H., et al. "A New Chemotherapeutic Investigation:
|
|
Piracetam Effects on Dyslexia." Annals of Dyslexia. 1984, Vol.
|
|
34, pp. 29-48.
|
|
Conners, et al. "Piracetam and Event-Related Potentials in Dyslexic
|
|
Children." Psychopharmacology Bulletin. 1984, Vol. 20, pp.
|
|
667-73.
|
|
Dimond, S.J., Browers, E.Y.M. "Increase in the Power of Human
|
|
Memory in Normal Man Through the Use of Drugs."
|
|
Psychopharmacology. 1976, Vol. 49, pp. 307-9.
|
|
Dilanni, M., et al. "The Effects of Piracetam in Children with
|
|
Dyslexia." Journal of Clinical Psychopharmacology. 1985, Vol.
|
|
5, pp. 272-8.
|
|
Donaldson, T. "Therapies to Improve Memory." Anti-Aging News. 1984,
|
|
No. 4, pp. 13-21.
|
|
Ferris, S.H., et al. "Combination of Choline/Piracetam in the
|
|
Treatment of Senile Dementia." Psychopharmacology Bulletin.
|
|
1982, Vol. 18, pp. 94-8.
|
|
Friedman, E., et al. "Clinical Response to Choline Plus Piracetam
|
|
in Senile Dementia: Relation to Red-Cell Choline Levels." The
|
|
New England Journal of Medicine. 1981, 304, No. 24, pp.
|
|
1490-1.
|
|
Giurgea, C.E. "The 'Nootropic' Approach to the Pharmacology of the
|
|
Integrative Activity of the Brain." Conditional Reflex. 1973,
|
|
Vol. 8, No. 2, pp. 108-15.
|
|
Ibid. "A Drug for the Mind." Chemtech. June 1980, pp. 360-65.
|
|
Giurgea, C.E., Salama, M. "Nootropic Drugs." Progress in
|
|
Neuropsychopharmacology. 1977, Vol. 1, pp. 235-47.
|
|
Kent, S. "Piracetam Increases Brain Energy." Anti-Aging News. 1981,
|
|
Vol. 2, No. 10, pp. 65-69.
|
|
Mindus, P., et al. "Piracetam-Induced Improvement of Mental
|
|
Performance: A Controlled Study on Normally Aging
|
|
Individuals." ACTA Psychiatrica Scandinavia. 1976, Vol. 54,
|
|
pp. 150-60.
|
|
Mondadori, C., et al. "Effects of Oxiracetam on Learning and Memory
|
|
in Animals: Comparison with Piracetam." Clinical
|
|
Neuropharmacology. 1986, Vol. 9, Supp. 13. New York: Raven
|
|
Press, pp. S27-S37.
|
|
Nickerson, V.J., Wolthuis, O.L. "Effect of the
|
|
Acquisition-Enhancing Drug Piracetam on Rat Cerebral Energy
|
|
Metabolism Comparison with Naftidrofuryl and Methamphetamine."
|
|
Biochemical Pharmacology. 1976, Vol. 25, pp. 2241-4.
|
|
Parducz, A. "Depletion of Synaptic Vesicle Lipids in Stimulated
|
|
Cholinergic Nerve Terminals." Alzheimer's Disease: Advances
|
|
in Basic Research and Therapies. Proceedings of the Third
|
|
Meeting of the International Study Group of the Treatment of
|
|
mory Disorders Associated with Aging. Zurich, Switzerland,
|
|
1984, pp. 217-26.
|
|
Pearson, D., Shaw, S. Durk Pearson & Sandy Shaw's Life Extension
|
|
Newsletter. October 1988, Vol 1, Number 8, p. 65.
|
|
Pellegata, R., et al. "Cyclic Gaba-Gabob Analogues." Presented at
|
|
VI International meeting of the International Society For
|
|
Neurochemistry, Copenhagen, August 21-26, 1977.
|
|
Pelton, R., Pelton, T.C. Mind Food & Smart Pills. New York:
|
|
Doubleday, 1989.
|
|
Pepeu, G., and Spignoli, G. Neurochemical Actions of "Nootropic
|
|
Drugs". Advances in Neurology. Vol. 51: Alzheimer's Disease.
|
|
New York: Raven Press, Ltd., 1990.
|
|
Pilch, H., et al. "Piracetam Elevates Muscarinic Cholinergic
|
|
Receptor Density in the Frontal Cortex of Aged But Not of
|
|
Young Mice." Psychopharmacology. 1988, 94, pp. 74-8.
|
|
Poschel, B.P.H. "New Pharmacologic Perspectives on Nootropic
|
|
Drugs." Handbook of Psychopharmacology. 1988, pp. 11-18, pp.
|
|
24-5.
|
|
Stegink, A.J. "The Clinical Use of Piracetam, a New Nootropic
|
|
Drug." Arzneimittelforschung. 1972, Vol. 22, No. 6, pp. 975-7.
|
|
U.B.C. Laboratories, Pharmaceutical Division. "Basic Scientific
|
|
and Clinical Data of Nootropil." Brussels, Belgium: U.B.C.
|
|
Laboratories, 1977.
|
|
Wilsher, C.R. "Piracetam and Dyslexia: Effects on Reading Tests."
|
|
Journal of Clinical Psychopharmacology. 1987, Vol. 7, No. 4,
|
|
pp. 230-7.
|
|
Wurtman, R.J., et al. "Piracetam Diminishes Hippocampal
|
|
Acetylcholine Levels in Rats." Life Science. 1981, Vol. 28,
|
|
pp. 1091-3.
|
|
Zhang, S., et al. "Effects of Cerebral GABA Level on Learning and
|
|
Memory." Pharmacologica Sinica. 1989 10(1): pp. 10-2.
|
|
|
|
|
|
Hydergine
|
|
|
|
Branconnier, R. "The Efficacy of the Cerebral Metabolic Enhancers
|
|
in the Treatment of Senile Dementia." Psychopharmacology
|
|
Bulletin. 1983, 19(2), pp. 212-20.
|
|
Copeland, R.L., Jr., et al. "Behavioral and Neurochemical Effects
|
|
of Hydergine in Rats." Archives of International
|
|
Pharmacodynamics. 1981, Vol. 252, pp. 113-23.
|
|
Emmenegger, H., Meier-Ruge, W. "The Actions of Hydergine on the
|
|
Brain." Pharmacology. 1968, Vol. 1, pp. 65-78.
|
|
Exton-Smith, A.N., et al. "Clinical Experience with Ergot
|
|
Alkaloids." Aging. New York: Raven Press, 1983, Vol. 23, p.
|
|
323.
|
|
Fanchamps, A. "Dihydroergotoxine in Senile Cerebral Insufficiency."
|
|
Aging. New York: Raven Press, 1983, Vol. 23, pp. 311-22.
|
|
Hindmarch, I., et al. "The Effects of an Ergot Alkaloid Derivative
|
|
(Hydergine) on Aspects of Psychomotor Performance, Arousal,
|
|
and Cognitive Processing Ability." The Journal of Clinical
|
|
Pharmacology. November-December 1979, pp. 726-31.
|
|
Hughes, J.R., et al. "An Ergot Alkaloid Preparation (Hydergine) in
|
|
the Treatment of Dementia: A Critical Review of the Clinical
|
|
Literature." Journal of the American Geriatrics Society. 1976,
|
|
Vol. 24, pp. 490-97.
|
|
Kleimola, T. "Generic Bioavailability Test." Turku, Finland: Leiras
|
|
Pharmaceuticals, 1982.
|
|
Nandy, K., Schneider, F.H. "Effects of Dihydroergotoxine Mesylate
|
|
on Aging Neurons in vitro." Gerontology. 1978, Vol. 24, pp.
|
|
66-70.
|
|
Otomo, E., et al. "Comparison of Vipocetine with Ifenprodil
|
|
Tartrate and Dihydroergotoxine Mesylate Treatment and Results
|
|
of Long-Term Treatment with Vinpocetine." Current Therapeutic
|
|
Research. 1985, Vol. 37, No. 5, pp. 811-21.
|
|
Pearson, D., Shaw, S. Life Extension: A Practical Scientific
|
|
Approach. New York: Warner Books, 1982.
|
|
Pelton, R., Pelton, T.C. Mind Food & Smart Pills. New York:
|
|
Doubleday, 1989.
|
|
Rao, D.B., Norris, J.R.. "A Double-Blind Investigation of Hydergine
|
|
in the Treatment of Cerebrovascular Insufficiency in the
|
|
Elderly." Johns Hopkins Medical Journal. 1971, Vol. 130, pp.
|
|
317-23.
|
|
Spiegel, R., et al. "A Controlled Long-Term Study with Ergoloid
|
|
Mesylates (Hydergine) in Healthy, Elderly Volunteers: Results
|
|
After Three Years." Journal of the Geriatrics Society. 1983,
|
|
Vol. 31, No. 9, pp. 549-55.
|
|
Weil, C., ed. "Pharmacology and Clinical Pharmacology of
|
|
Hydergine." Handbook of Experimental Pharmacology. New York:
|
|
Springer-Verlag, 1978.
|
|
Yesavage, J.A., et al. "Dihydroergotoxine: 6-Mg versus 3-Mg Dosage
|
|
in the Treatment of Senile Dementia. Preliminary Report."
|
|
Journal of the American Geriatrics Society. 1979, Vol. 27, No.
|
|
2, pp. 80-82.
|
|
Yoshikawa, M., et al. "A Dose-Response Study with Dihydroergotoxine
|
|
Mesylate in Cerebrovascular Disturbances." Journal of the
|
|
American Geriatrics Society. 1983, Vol. 31, No. 1, pp. 1-7.
|
|
|
|
Vasopressin
|
|
|
|
De Wied, D., et al. "Vasopressin and Memory Consolidation."
|
|
Perspectives in Brain Research. New York: Elsevier Scientific
|
|
Publishing, 1975.
|
|
Gold, P.W., et al. "Effects of l-Desamo-8-Arginine Vasopressin on
|
|
Behavior and Cognition in Primary Affective Disorders." The
|
|
Lancet. November 10, 1979, pp. 992-94.
|
|
Laczi, F., et al. "Effects of Lysine-Vasopressin and
|
|
l-Deamino-8-D-Arginine-Vasopressin on Memory in Healthy
|
|
Individuals and Diabetes Insipidus Patients."
|
|
Psychoneuroendocrinology. 1982, Vol. 7, No. 2, pp. 185-92.
|
|
Legros, J. J., et al. "Influence of Vasopressin on Learning and
|
|
Memory." The Lancet. January 7, 1978, pp. 41-42.
|
|
Oliveros, J.C., et al. "Vasopressin in Amnesia." The Lancet.
|
|
January 7, 1978, p. 42.
|
|
Pearson, D., Shaw, S. Life Extension: A Practical Scientific
|
|
Approach. New York: Warner Books, 1982.
|
|
Pelton, R., Pelton, T.C. Mind Food & Smart Pills. New York:
|
|
Doubleday, 1989.EOF
|
|
|
|
=============================================================================
|
|
|
|
My experience so far has been with piracetum, hydergine, DMAE,
|
|
L-Glutamine (which, I think, is the same as PCA), and choline. So far
|
|
the results have been mixed. Of course, so have the substances. My
|
|
approach has been to try out some of these first, to try for immediate
|
|
(and easily obtained) effects, with an eye toward getting more
|
|
scientific over time. My impressions:
|
|
|
|
PIRACETUM
|
|
|
|
I have had at least one extraordinarily good experience which I
|
|
believe was caused by piracetum. I "attack" dosed at 4g, then took .8g
|
|
three times per day for two days. On the third day, out of the blue, I
|
|
suddenly started feeling great, energetic, fast, etc. It was a feeling
|
|
similar to caffiene, but without as much adrenal response. In keeping
|
|
with other accounts that I have heard, music became very intense, and I
|
|
had a strong desire to play it very loud. I tried playing the guitar and
|
|
it seemed to come more easily to me. Unfortunately, this eventually went
|
|
away, and I haven't had a similar experience since, although I haven't
|
|
pushed it much. It seems that my verbal memory (vocabulary) has
|
|
increased slightly, in keeping with the research, but it is not a clear
|
|
difference, if one even exists.
|
|
|
|
DMAE
|
|
|
|
>From what I can tell, DMAE works as advertised, with two main effects:
|
|
(1) it seems to slowly build a stimulation, which, while not constant,
|
|
is persistant, (2) it seems to regulate and reduce need for sleep. These
|
|
effects have appeared while taking ~300mg of DMAE/day, along with 3g
|
|
choline (+1g B-5), and varying amounts of piracetum. Therefore, it is
|
|
hard to sceintifically attribute the effects to DMAE. However,
|
|
intuitively (knowing varying doses, etc), it seems to me that DMAE has
|
|
provided the bulk of these effects.
|
|
|
|
HYDERGINE
|
|
|
|
I have yet to experience the much touted synergy between hydergine and
|
|
piracetum, even after taking 4.5mg hydergine + 4g piracetum. I do know
|
|
that the warnings against taking too much hydergine, esp. at first,
|
|
should be taken seriously. It can make you nauseated.
|
|
|
|
OTHERS
|
|
|
|
L-Glutamine was the first thing that I tried. I percieved no effect from
|
|
this whatsoever. I'd be interested to hear about experiences with
|
|
arginine pyroglutamate, since that is supposed to be the more potent
|
|
form. I've always taken the choline + B5 with some combination of the
|
|
above, so it would be hard to break out the effect. My episodic memory
|
|
of the past seems enriched, but that remains hard to discern.
|
|
|
|
That about does it. So far, DMAE seems like the only real win, since it
|
|
appears to cut need for sleep by a bit---therefore, more day to work
|
|
with. More experimentation will certainly be conducted.
|
|
|
|
=============================================================================
|
|
|
|
My own experience is with piracetam, centrophenoxine (Lucidril), and
|
|
vasopressin (Diapid). Piracetam might have had some effects, but made my
|
|
eyes so red on the days that I took it that I decided it was not worth
|
|
continuing. Vasopressin, as Max said, is mainly useful when the brain's
|
|
supply of neurotransmitters is either depleted (following a caffeine or
|
|
other stimulant binge) or suppressed (by alcohol or other CNS depressant)
|
|
-- I consider it the long-sought "sober-up" treatment.
|
|
|
|
Centrophenoxine gave me the most dramatic results -- I did not measure
|
|
them by any kind of psychometric tests, but I felt more alert, and
|
|
experienced faster and more reliable recall than previously. Since
|
|
Lucidril works by making a permanent brain change (enabling brain
|
|
metabolism to remove life-long accumulations of the aging pigment
|
|
lipofuscin from the neurons), its effects are cumulative -- you continue
|
|
to feel sharper even after you quit taking the drug.
|
|
|